insidermonkey.comSEP 223 min read$CORT

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

Original reporting

insidermonkey.com

Published Sep 22, 2026, 7:00 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 22, 2026, 7:19 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle — source image — Source · insidermonkey.com

Decision brief

The 30-second read

$CORTBullishHigh

Why it matters

The EU regulator's positive opinion could unlock a comparable market of ~20,000 patients, potentially adding $100‑$200 M in annual revenue.

Market read

Regulatory progress in Europe may drive CORT stock higher and influence biotech sector sentiment.

What to watch

High launch costs and limited patient pool may constrain long‑term revenue growth.

Relevance 8/10Novelty 8/10Timing: after CHMP recommendation (Sept 18) and before European Commission decision

Background

Corcept Therapeutics recently launched Lifyorli in the US, generating strong Q1 sales and raising full‑year guidance.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CORTBullishHigh confidence

Context

CHMP recommended approval for Corcept's cancer drug relacorilant, a new regulatory milestone.

Expected impact

Potential upside as investors price in European market entry.

Evidence & confidence

Regulatory recommendation is a primary catalyst; market typically reacts favorably to EU approvals.

Market effects

Sector

Strengthens outlook for oncology biotech sector and may lift peers with similar EU pathways.

Regional

European markets could see modest gains in biotech exposure.

Global

Adds to global biotech momentum as US sales already strong.

Counterpoint

What could challenge this read

European approval could be delayed or face post‑launch pricing pressure, limiting upside.

Key entities

company
Corcept Therapeutics
Biotech firm developing relacorilant for ovarian cancer.
regulatory_body
CHMP
Committee for Medicinal Products for Human Use, EU regulator.

Read at source ← All news

SEP 19

$CORTHighAI 8/10

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.

stocktwits.com2 min

SEP 18

$CORTMedAI 8/10

Corcept's Lifyorli Gets Positive EU Opinion For Platinum-Resistant Ovarian Cancer

Corcept Therapeutics (CORT) announced that the EMA's CHMP recommended approval of relacorilant for platinum-resistant ovarian cancer, based on Phase 2 and 3 trial data showing improved survival rates. The European Commission will decide by Q4 2026. CORT's stock closed at $114.86, up 2.73%, and was at $115.45 in premarket trading.

rttnews.com2 min

SEP 18

$CORTHighAI 9/10

Corcept Therapeutics Incorporated: Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant)

Corcept Therapeutics (CORT) announced the European Medicines Agency's CHMP recommended EU approval for relacorilant, combined with nab-paclitaxel, to treat platinum-resistant ovarian cancer. The recommendation follows positive Phase 2 and Phase 3 trial results showing improved survival rates. The EC will decide by Q4 2026. Relacorilant is already FDA-approved in the U.S. for the same indication.

finanznachrichten.de2 min

AUG 6

$CORTHighAI 9/10

Raised Guidance Lifts Corcept to 52-Week High

Corcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.

yahoo.com3 min

JUL 31

$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

yahoo.com7 min